Obstructive Sleep Apnea
Repeated airway collapse during sleep
What it is
Obstructive sleep apnea is the repeated collapse of the upper airway during sleep, causing pauses in breathing, drops in blood oxygen, and fragmented sleep. It is extremely common, and most people who have it do not know — it is one of the most under-diagnosed conditions in medicine.
Why it matters
OSA is an upstream driver of an enormous amount of downstream disease. It causes and worsens hypertension (especially treatment-resistant hypertension), atrial fibrillation, insulin resistance, fatty liver, and low testosterone, and it substantially raises the risk of motor-vehicle crashes through daytime sleepiness. It is also highly treatable. If you are being investigated for tiredness, resistant high blood pressure, or low testosterone, this is one of the first things that should be excluded — and frequently isn't.
What BioSignal knows about treating this
What works for Obstructive Sleep Apnea
BioSignal’s clinical summary, most important first.
- CPAP — the standard treatment; reliably reduces events, sleepiness, and blood pressure
- Weight loss — highly effective, and it treats the cause rather than the symptom
- Tirzepatide — now approved for moderate-to-severe OSA in people with obesity, after trials showing substantial reductions in breathing events
- Mandibular advancement devices (for mild-to-moderate disease, or CPAP intolerance)
- Positional therapy where events are strongly supine-dependent
- Reducing alcohol and sedatives before bed
- Surgery or hypoglossal nerve stimulation in selected patients
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Blood Pressure MedicationHigh confidence
Among the highest-value medicines ever made. The evidence isn't the problem — about half of people stop taking them, and that's where the strokes are.
- AlcoholHigh confidence
A Group 1 carcinogen with dose-dependent harms. The heart-protection belief does not survive the methods designed to test it. Cutting back helps, even without quitting.
- TirzepatideHigh confidence
The most effective approved weight-loss medication in head-to-head and placebo-controlled trials; cardiovascular-outcome proof for tirzepatide specifically is still pending.
- Testosterone TherapyModerate confidence
Effective for genuine hypogonadism; no established benefit at normal levels. Suppresses fertility. Ask why testosterone is low before treating the number.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Obesity (the dominant modifiable risk factor)
- Male sex (though it is substantially under-diagnosed in women)
- Older age
- Large neck circumference and craniofacial anatomy (a small or set-back jaw)
- Alcohol and sedatives (they relax the airway)
- Menopause (risk rises markedly afterwards)
- Smoking
- Nasal obstruction
How it's diagnosed
Diagnosis requires a sleep study — either in-laboratory polysomnography or a home sleep apnea test — which measures the apnea-hypopnea index (AHI), the number of breathing events per hour. Symptoms plus an AHI of 5 or more, or an AHI of 15 or more regardless of symptoms, establishes the diagnosis. Screening questionnaires such as STOP-BANG or the Epworth Sleepiness Scale identify who should be tested; they do not diagnose it.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related peptide families
Related body systems
Frequently asked questions
I'm exhausted all the time. Could this be it?
It could, and it is worth taking seriously — OSA is one of the most under-diagnosed conditions in medicine, and persistent daytime sleepiness is its cardinal symptom. Snoring, witnessed pauses in breathing, waking unrefreshed, morning headaches, and needing to urinate at night are the other clues. Fatigue has many causes, but this one is common, consequential, and treatable, and it is frequently missed for years.
My testosterone is low. What has that got to do with sleep?
A great deal. Testosterone is largely produced during sleep, and OSA fragments sleep and starves the body of oxygen — so untreated OSA suppresses testosterone. Treating the sleep apnea can restore it. This is why 'why is your testosterone low?' is a more useful question than 'should you take testosterone?': prescribing testosterone here treats the number while leaving the cause running, and testosterone can itself worsen sleep apnea.
Does CPAP prevent heart attacks and strokes?
This is where we have to be careful, because the honest answer is more complicated than the marketing. CPAP clearly reduces breathing events, daytime sleepiness, and blood pressure — those benefits are real and worth having. But randomised trials have NOT convincingly shown that CPAP reduces heart attacks and strokes, which surprised many people. Poor adherence is a major suspected reason: people wear the mask for too few hours to benefit. So CPAP is genuinely worth using — just not on the promise that it will definitely prevent a cardiovascular event.
Can weight-loss medication treat sleep apnea?
Yes, and this is a genuine recent advance. Tirzepatide is now approved for moderate-to-severe obstructive sleep apnea in people with obesity, following trials that showed substantial reductions in breathing events. It treats a root cause rather than splinting the airway open each night, which is a meaningfully different proposition from CPAP.
Evidence summary
OSA's causal contribution to hypertension — particularly resistant hypertension — insulin resistance, atrial fibrillation, and low testosterone is well established, as is its role in motor-vehicle crash risk. CPAP has strong randomised evidence for reducing breathing events, sleepiness, and blood pressure, but randomised trials have NOT convincingly demonstrated a reduction in cardiovascular events, with poor adherence a leading suspected explanation. Weight loss is highly effective, and tirzepatide has randomised evidence and regulatory approval for moderate-to-severe OSA in obesity.
References & sources
- AASM clinical practice guidelines on the diagnosis and treatment of obstructive sleep apnea
- SAVE trial (CPAP and cardiovascular events — null for the primary outcome)
- SURMOUNT-OSA (tirzepatide in moderate-to-severe OSA with obesity)
- Literature on OSA, resistant hypertension, and suppression of testosterone
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback